Voronoi Amends Clinical Trial Application for VRN110755 to Add France Spain Poland for Global Phase 1/2 Study, No Capital Changes
Voronoi announced on June 22, 2026 a correction to its clinical trial plan change application, adding France, Spain, and Poland for the European Medicines Agency submission.
The addition expands the trial to Europe alongside existing regions North America, Asia, and Oceania for the global Phase 1/2 study of VRN110755 in EGFR-mutant non-small cell lung cancer.
The trial targets 391 patients to assess safety and efficacy over up to 6 years as a multicenter study.
This disclosure is a routine amendment with no capital changes, share dilution, or governance events affecting shareholder value.
[AI Summary]Voronoi's addition of EU countries to its clinical trial application for VRN110755 represents an operational step with no immediate financial impact, maintaining a neutral outlook for shareholder value amid clinical uncertainties.
KOSDAQ Filing Information
[Correction of Description] Major Management Matters Related To Investment Decision (Application For Approval Of Clinical Trial Plan Change) (Phase 1/2 Clinical Trial Of VRN110755)